romesh
6 years ago
Predictive Analytics In Healthcare Industry Value Will Climb Throughout the Year 2025
The global predictive analytics in healthcare market was valued at $1,806 million in 2017, and is estimated to reach $8,464 million at a CAGR of 21.2% from 2018 to 2025. Predictive analytics finds a pattern in historical and transactional data and uses it to identify risks and opportunities for future. Based on the available descriptive data, predictive analytics uses different techniques, which include machine learning, statistical techniques, and predictive modelling to evaluate and determine the probable future.
The global predictive analytics in healthcare market is segmented based on application, component, end user, and region. Based on application, it is divided into operations management, financial data analytics, population health management, and clinical. Based on component, the market is categorized into hardware, software, and service. Based on end user, the market is classified into healthcare payer, healthcare provider, and others.
stocktrademan
10 years ago
$MDRX DD Notes ~ http://www.ddnotesmaker.com/MDRX
bullish
quick trade
$MDRX recent news/filings
## source: finance.yahoo.com
Thu, 11 Dec 2014 18:30:02 GMT ~ Allscripts Deploys eAuth ePA Solution, Boosts EHR Portfolio
[Zacks] - Healthcare information technology solutions provider, Allscripts Healthcare Solutions, Inc. (MDRX), recently announced the distribution of a new electronic prior authorization (ePA) solution named Allscripts ...
read full: http://finance.yahoo.com/news/allscripts-deploys-eauth-epa-solution-183002929.html
*********************************************************
Thu, 11 Dec 2014 17:50:02 GMT ~ Shares Fall as athenahealth's 2015 Outlook Fails to Impress
[Zacks] - Shares of athenahealth Inc. (ATHN) declined almost 2% ($2.26) to $119.43 after the company's reaffirmed 2014 guidance and 2015 initial guidance failed to cheer investors.
read full: http://finance.yahoo.com/news/shares-fall-athenahealths-2015-outlook-175002069.html
*********************************************************
Wed, 10 Dec 2014 19:50:02 GMT ~ Allscripts Healthcare (MDRX) Grows on Higher EHR Adoption
[Zacks] - We note that Allscripts Healthcare Solutions Inc. (MDRX) continues to benefit from the HITECH Act, as reflected by the significant number of client admissions during the year and additional related orders ...
read full: http://finance.yahoo.com/news/allscripts-healthcare-mdrx-grows-higher-195002525.html
*********************************************************
Wed, 10 Dec 2014 17:56:52 GMT ~ Allscripts and Express Scripts Collaborate to Deploy Allscripts eAuth Electronic Prior Authorization Solution
[at noodls] - Leading Pharmacy Benefit Manager Leverages Point of Care Prior Authorization for Prescriptions to Improve Efficiencies, Foster Adherence and Reduce Costs CHICAGO, Dec. 10, 2014 (GLOBE NEWSWIRE) -- Allscripts ...
read full: http://www.noodls.com/view/B8E9F44AADFC442CCFAA8708AA6257C8900A554E
*********************************************************
Wed, 10 Dec 2014 13:01:00 GMT ~ Allscripts and Express Scripts Collaborate to Deploy Allscripts eAuth Electronic Prior Authorization Solution
[GlobeNewswire] - CHICAGO -- Allscripts and Express Scripts have announced the deployment of Allscripts eAuth, a new electronic prior authorization (ePA) solution that transacts an electronic prior authorization for Express ...
read full: http://finance.yahoo.com/news/allscripts-express-scripts-collaborate-deploy-130100020.html
*********************************************************
$MDRX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$MDRX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MDRX/company-info
Ticker: $MDRX
OTC Market Place: Not Available
CIK code: 0001124804
Company name: Allscripts Healthcare Solutions Inc.
Incorporated In: DE, USA
$MDRX share structure
## source: otcmarkets.com
Market Value: $2,319,971,091 a/o Dec 24, 2014
Shares Outstanding: 180,261,934 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$MDRX extra dd links
Company name: Allscripts Healthcare Solutions Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MDRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MDRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MDRX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/news - http://finance.yahoo.com/q/h?s=MDRX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MDRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MDRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MDRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Allscripts+Healthcare+Solutions+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Allscripts+Healthcare+Solutions+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Allscripts+Healthcare+Solutions+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MDRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001124804&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MDRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MDRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MDRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MDRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MDRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MDRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MDRX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MDRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MDRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MDRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MDRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MDRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MDRX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MDRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MDRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MDRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MDRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MDRX
$MDRX DD Notes ~ http://www.ddnotesmaker.com/MDRX
Globaltrnr
12 years ago
I personally received your various emails over the last week (and today) regarding Allscripts announcements on Wednesday, December 19.
I understand your concern regarding Allscripts shareholder value and what the future may hold.
Let me offer you some facts for consideration.
First, during the strategic alternatives process, Allscripts Board of Directors conducted a thorough and rigorous review of alternatives. The Board concluded that the best course at this time is to develop Allscripts long-term potential under the direction of a new management team.
Over the coming weeks and months, Paul Black, our new CEO and healthcare IT industry veteran, will work with his leadership team on enhancing our operational efficiency, solutions sales efforts and our financial strategy to ensure that Allscripts is positioned for success and value enhancement.
Regarding your statement on a share repurchase, Allscripts currently has approximately $125MM remaining on its existing $400MM share repurchase authorization announced in May, 2011. Our leadership team is evaluating our capital allocation strategy and will update the market on our Q4 2012 earnings call, which will take place in the mid-February timeframe.
In the meantime, Allscripts fundamentals remain strong – a large client base, strong financial position, one of the industry’s largest investments in R&D, and a refreshed product portfolio based on Open technology.
I hope this perspective is helpful and we again understand and appreciate your concerns as an Allscripts shareholder.
Sincerely,
Seth
Seth R. Frank | Vice President, Investor Relations
Allscripts | 222 Merchandise Mart | Suite 2024 | Chicago, IL | 60654
312.506.1213 | P?
mlkrborn
12 years ago
No sale: $9
Allscripts names new CEO to spearhead recovery
Wed, Dec 19 2012
Thu Dec 20, 2012 12:07pm EST
* New CEO Black sketches plans for role at Allscripts
* Chairman says strategic review process was rigorous
* Stock falls as much as 17 pct after announcement (Updates with background)
Dec 20 (Reuters) - Shares of Allscripts Healthcare Solutions Inc fell as much as 17 percent on Thursday after the company abandoned plans to sell itself and instead introduced new management to run the company as an independent entity.
Allscripts, which sells systems that enable hospitals and physicians to share patient records electronically, announced the changes late on Wednesday.
On Thursday the company's chairman, Dennis Chookaszian, told analysts on a conference call that the board had conducted a rigorous review of its options and ultimately decided that the best way to create value for shareholders was to exploit the company's long-term growth potential.
Allscripts named Paul Black, former chief operating officer at rival Cerner Corp and an Allscripts board member, to replace Glen Tullman, who led the company for 15 years.
Black, who addressed shareholders on the call, said his goals include freshening the company's product line, enhancing operating efficiencies and working to retain existing clients. He said he will spend time meeting with key constituents before laying out his plan in detail.
The company declined to provide a financial outlook except to say it was happy with the way the fourth quarter started. Black said he expects the company to benefit from having clarity now that the review process is over.
"There has been a lot of disruption in the marketplace," he said. "A lot of people were hesitant to make a decision until they knew who they would be working with."
Chookaszian declined to disclose whether the board's decision to remain independent was unanimous, saying the board "doesn't comment on its decisions."
The decision follows months of turmoil at Allscripts, which in June, under pressure, installed three board members nominated by the hedge fund HealthCor Management, which had lobbied intensively for the removal of Tullman.
Allscripts shares were down 14.6 percent at $9.13 on the Nasdaq at mid-day on Thursday.
Several private equity groups, including Blackstone Group LP , were apparently interested in Allscripts, but sources familiar with the situation told Reuters suitors had become concerned about Allscripts' declining earnings and market-share losses to larger rivals such as Cerner. (Reporting by Toni Clarke in Boston; Editing by Matthew Lewis and Steve Orlofsky)
Down to $9 with cancelling sale:Down to $9. No sale.
Daybull
13 years ago
$400M Buyback of Shares
Eat Crow Cramer: Buy, Buy, Buy, back to $16.
Allscripts Announces Increase To Stock Repurchase Program And Names Board Chairman --Expanded Repurchase Program Adds $200 Million to $148 Million Remaining on Repurchase Program Announced in May 2011 --Elects Dennis Chookaszian Chairman of the Board CHICAGO, April 30, 2012 /PRNewswire via COMTEX/ -- Allscripts Healthcare Solutions, Inc. (allscripts - nasdaq:MDRX) today announced that its Board of Directors has authorized management to repurchase an additional $200 million of Allscripts common stock, bringing the total repurchase authorization to $400 million. Since May 5, 2011, the Company has repurchased approximately $52 million of Allscripts common stock under its previously approved $200 million share repurchase program. Repurchases may be made pursuant to Rule 10b5-1 or 10b-18 of the Securities Exchange Act of 1934, as amended. Any share repurchases may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means. Any repurchase activity will depend on factors such as the Company's working capital needs, cash requirements for investments, debt repayment obligations, stock price, and economic and market conditions. There is no guarantee as to the exact number of shares or value thereof that will be repurchased under the stock repurchase program. The stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. Allscripts also announced today that its Board of Directors has elected Dennis Chookaszian Chairman. Mr. Chookaszian, who has been a director since September 2010, has a wide range of experience as a chief executive officer and public company board member. From 1999 until 2001, Mr. Chookaszian served as Chairman and Chief Executive Officer of mPower, Inc., a financial advice provider focused on the on-line management of 401(k) plans. Mr. Chookaszian served as Chairman and Chief Executive Officer of CNA Insurance Companies from 1992 to 1999 and as Chairman of the Executive Committee from 1999 to 2002. During his 27-year career with CNA, Mr. Chookaszian held several management positions, including President and Chief Operating Officer from 1990 to 1992 and Chief Financial Officer from 1975 to 1990. Mr. Chookaszian currently serves as a director of CME Group, Inc., Career Education Corporation and Internet Patent Corp. Mr. Chookaszian also served as Chairman of the Financial Accounting Standards Advisory Council (FASAC), the advisory council to the Financial Accounting Standards Board (FASB), from January 2007 to December 2011. About Allscripts Allscripts (MDRX) delivers the insights that healthcare providers require to generate world-class outcomes. The company's Electronic Health Record, practice management and other clinical, revenue cycle, connectivity and information solutions create a Connected Community of Health(TM) for physicians, hospitals and post-acute organizations. To learn more about Allscripts, please visit http://www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements with the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation ("Eclipsys") will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate, including the risk that existing clients will switch to products of competitors; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products or other product quality issues; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Annual Report on Form 10-K for 2011 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.
DayBull
mlkrborn
13 years ago
MDRX is down to $10 with weak earnings and leadership change:
Allscripts shares plunge on weak outlook, board changes
Allscripts' development costs hurt profit, sees board changes
Thu, Apr 26 2012
Fri Apr 27, 2012 9:24am EDT
(Reuters) - Allscripts Healthcare Solutions Inc's shares plunged 42 percent in premarket trade on Friday, after the company forecast weak full-year earnings, hurt by software development costs and weaker bookings.
On Thursday, the healthcare information technology provider reported a lower-than-expected quarterly profit and also announced the resignation of its CFO, three directors and board Chairman Phil Pead.
Citigroup analyst George Hill said the results were strongly disappointing and downgraded the company's stock to "neutral" from "buy."
Hill said he was most troubled by the loss of long tenured CFO Bill Davis, who had been the public face of Allscripts to investors for many years.
"We suspect CEO Glen Tullman won a power struggle at the 11th hour leading to the board departures," Hill said.
"Too few customers are buying its products, due to lack of confidence or satisfaction," Barclays Capital analyst Lawrence Marsh wrote in a note.
Allscripts shares were trading at $9.27 in premarket trade. They had closed at $16.02 Thursday on the Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Joyjeet Das)
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
Renee
9 months ago
BLACKBIRDSR-71
3 years ago
whytestocks
4 years ago
ClayTrader
4 years ago
crudeoil24
4 years ago
xanadu
12 years ago
Penny Roger$
13 years ago
Hot Features
Premium
